University of South Florida pulmonologist Dr. Jose Herazo-Maya has focused his career on researching treatments for pulmonary fibrosis, a devastating and deadly lung disease. Pulmonary fibrosis in ...
The study of long COVID remains in its infancy, with no FDA-approved treatment available, but the pandemic may be spawning new research into other medical areas, says the head of Northwestern's long ...
Credit: Getty Images. The first step in diagnosing idiopathic pulmonary fibrosis is ruling out other known causes of interstitial lung disease. Making an accurate diagnosis of IPF is critical because ...
Idiopathic pulmonary fibrosis, a rare progressive disease characterized by fibrosis in the alveoli of the lungs, has a median survival of 3 to 5 years if left untreated. Inhaled treprostinil slowed ...
Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone, are ...
When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF) might be the culprit behind the concerning symptoms. This rare yet devastating lung disease ...
Petrovax announced today the positive results from “Long-CoV-III-21,” a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult ...
BECHTELSVILLE, Pennsylvania (WPVI) -- Most of us take breathing for granted. But with pulmonary fibrosis, patients lose that despite the best medical efforts. That outcome is on the verge of change.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results